Although the mechanisms underlying TKI resistance in lung cancers are diverse, the activation of downstream signaling pathways that converge with the EGFR pathway to activate the transcription of proliferation-related genes represents the predominant molecular event in EGFR-TKI-resistant neoplastic cells [5, 30, 31]. This evidence concerns the gene EGFR and lung cancer.